JNJ-7706621
JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC50s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B, respectively[1][2][3].
Product Specifications
CAS Number
443797-96-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Aurora Kinase; CDK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/JNJ-7706621.html
Concentration
10mM
Purity
99.39
Solubility
DMSO : ≥ 125 mg/mL
Smiles
O=S(C1=CC=C(NC2=NN(C(C3=C(F)C=CC=C3F)=O)C(N)=N2)C=C1)(N)=O
Molecular Formula
C15H12F2N6O3S
Molecular Weight
394.36
Precautions
H302, H315, H319, H335
References & Citations
[1]Huang S, et al. Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16 (14) :3639-41. Epub 2006 May 6.|[2]Matsuhashi A, et al. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. Curr Cancer Drug Targets. 2012 Jul;12 (6) :625-39.|[3]Danhier F, et al. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. Int J Pharm. 2010 Jun 15;392 (1-2) :20-8.|[4]Emanuel S, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005 Oct 1;65 (19) :9038-46.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Aurora A; Aurora B; CDK1; CDK2; CDK3; CDK4; CDK6
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
orb2330953 100 µL
Occludin Recombinant Rabbit mAb, BF647 conjugated
Sign In for Pricing
View Details 
